Extracted from this filing and checked against the source text.
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
Aspire Biopharma Holdings, Inc. entered into Purchase Agreement with FireFish TopCo, LLC valued at Purchase price $30,000,000 plus $800,000 deferred revenue credit, minus tax and debt adjustments (effective 2026-06-10).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- FireFish TopCo, LLC
- Value
- Purchase price $30,000,000 plus $800,000 deferred revenue credit, minus tax and debt adjustments
- Effective
- 2026-06-10
Exact text from the filing
On June 10, 2026, Aspire Biopharma Holdings, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with FireFish TopCo, LLC (the “Seller”, and, collectively with its Subsidiaries listed in Annex A of the Purchase Agreement, “Sellers”), pursuant to which (i) the Seller agreed to sell, and cause the applicable Sellers to sell, and the Company agreed to purchase or cause certain of its Affiliates to purchase, all of the equity interests in certain of Seller’s subsidiaries set forth in Annex C of the Purchase Agreement (the aforementioned equity interests, collectively, the ‘Transferred Equity Interests”, and such subsidiaries, “Transferred Entities”), free and clear of all Liens, other than the Permitted Liens and in accordance with the applicable Local Transfer Documents and (ii) the Seller agreed to sell, and cause the applicable Sellers to sell, and the Company agreed to purchase, or cause certain of its affiliates to purchase, all of the assets of the other
View on SEC.gov